Key result
HMGB1 inhibition partially reverses pressure overload-induced cardiac hypertrophy and dysfunction in mice.
Answers are grounded in this paper and cite their sources.
Inflammation plays a key role in pressure overload-induced cardiac hypertrophy and heart failure, but the mechanisms have not been fully elucidated. High-mobility group box 1 (HMGB1), which is increased in myocardium under pressure overload, may be involved in pressure overload-induced cardiac injury. The objectives of this study are to determine the role of HMGB1 in cardiac hypertrophy and cardiac dysfunction under pressure overload. Pressure overload was imposed on the heart of male wild-type mice by transverse aortic constriction (TAC), while recombinant HMGB1, HMGB1 box A (a competitive antagonist of HMGB1) or PBS was injected into the LV wall. Moreover, cardiac myocytes were cultured and given sustained mechanical stress. Transthoracic echocardiography was performed after the operation and sections for histological analyses were generated from paraffin-embedded hearts. Relevant proteins and genes were detected. Cardiac HMGB1 expression was increased after TAC, which was accompanied by its translocation from nucleus to both cytoplasm and intercellular space. Exogenous HMGB1 aggravated TAC-induced cardiac hypertrophy and cardiac dysfunction, as demonstrated by echocardiographic analyses, histological analyses and foetal cardiac genes detection. Nevertheless, the aforementioned pathological change induced by TAC could partially be reversed by HMGB1 inhibition. Consistent with the in vivo observations, mechanical stress evoked the release and synthesis of HMGB1 in cultured cardiac myocytes. This study indicates that the activated and up-regulated HMGB1 in myocardium, which might partially be derived from cardiac myocytes under pressure overload, may be of crucial importance in pressure overload-induced cardiac hypertrophy and cardiac dysfunction.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2015) studied Pressure overload-induced cardiac hypertrophy and heart failure. Recombinant HMGB1 and HMGB1 box A vs. PBS was evaluated on Cardiac hypertrophy and cardiac dysfunction. Exogenous HMGB1 aggravated transverse aortic constriction-induced cardiac hypertrophy and dysfunction in male mice, whereas HMGB1 inhibition partially reversed these pathological changes.
Synapse has enriched 10 related papers. Consider them for comparative context: